NASDAQ:DXR Daxor (DXR) Stock Price, News & Analysis → A new way to collect income from stocks (From DTI) (Ad) Free DXR Stock Alerts $9.94 +0.14 (+1.43%) (As of 04/24/2024 ET) Add Compare Share Share Today's Range$9.92▼$9.9450-Day Range$7.19▼$9.8052-Week Range$7.11▼$13.13Volume910 shsAverage Volume3,310 shsMarket Capitalization$47.12 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsFinancialsInsider TradesSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsFinancialsInsider TradesSEC FilingsShort InterestSocial Media Get Daxor alerts: Email Address Ad Crypto Swap ProfitsDid You Get Your Free Bitcoin Yet?And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.>> Register right here About Daxor Stock (NASDAQ:DXR)Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee.Read More DXR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DXR Stock News HeadlinesApril 10, 2024 | globenewswire.comDaxor Corporation Announces New Hospital Account at Leading Chicago HospitalMarch 25, 2024 | globenewswire.comDaxor Corporation Acquires Volumex® and Megatope® From Its Existing Supplier Along With Glofil® to Enhance Existing Suite of DiagnosticsApril 24, 2024 | Insider Financial (Ad)Thousands of investors use this no cost solution | Do you? In today’s volatile markets we are all looking for the edge. But imagine tapping into a world where every investment move has the potential to be ahead of the curve. Most investors have heard of the publication Insider Financial. For nearly a decade, they've unlocked doors to opportunities tucked away from the public eye, guiding over a million investors with well researched information before it hits the mainstream media.March 22, 2024 | globenewswire.comDaxor Corporation to Hold Investor Call Discussing Fiscal Year 2023 Financial Results and Corporate Update on March 25, 2024March 18, 2024 | globenewswire.comDaxor Corporation Reports Increase in NAV to $7.08 Per Share and 31.8 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2023March 18, 2024 | globenewswire.comDaxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to ShareholdersMarch 11, 2024 | globenewswire.comDaxor Announces Sales to Three New Hospitals Furthering Expansion of Its User BaseMarch 8, 2024 | globenewswire.comMulti-Center Study Presented by Duke at Heart Failure Therapeutics Conference Highlights Daxor's Unique Clinical Utility for Heart Failure PatientsApril 24, 2024 | Insider Financial (Ad)Thousands of investors use this no cost solution | Do you? In today’s volatile markets we are all looking for the edge. But imagine tapping into a world where every investment move has the potential to be ahead of the curve. Most investors have heard of the publication Insider Financial. For nearly a decade, they've unlocked doors to opportunities tucked away from the public eye, guiding over a million investors with well researched information before it hits the mainstream media.February 26, 2024 | globenewswire.comDaxor Corporation to Exhibit at the Technology and Heart Failure Therapeutics ConferenceSee More Headlines Receive DXR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Daxor and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/24/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:DXR CUSIPN/A CIK27367 Webwww.daxor.com Phone212-244-0555Fax212-244-0806EmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares4,740,000Free Float1,866,000Market Cap$47.12 million OptionableNot Optionable Beta-0.46 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMr. Michael Richard Feldschuh (Age 55)Chairman, President & CEO Comp: $100kMr. Jonathan Adam Feldschuh (Age 59)Chief Scientific Officer & Director Comp: $127.92kMr. Robert J. Michel CPA (Age 67)CPA, M.B.A., CFO, Chief Compliance Officer & Corporate Secretary Ms. Linda CooperVice President of Development & OperationsMs. Kathryn A. KornafelSenior VP of Marketing & Commercial DevelopmentMr. Guido ManzoVice President of SalesMs. Jean OertelSenior Vice President Commercialization & Customer ExperienceMore ExecutivesKey CompetitorsApyx MedicalNASDAQ:APYXBeyond AirNASDAQ:XAIRSEP AcquisitionNASDAQ:SEPACytosorbentsNASDAQ:CTSOInspireMDNYSE:NSPRView All CompetitorsInsidersRobert J MichelBought 750 shares on 3/27/2024Total: $6,525.00 ($8.70/share)Michael Richard FeldschuhBought 800 shares on 12/1/2023Total: $6,240.00 ($7.80/share)Robert J MichelBought 180 shares on 12/1/2023Total: $1,395.00 ($7.75/share)Robert J MichelBought 500 shares on 11/24/2023Total: $3,970.00 ($7.94/share)Michael Richard FeldschuhBought 401 shares on 11/9/2023Total: $3,147.85 ($7.85/share)View All Insider Transactions DXR Stock Analysis - Frequently Asked Questions How have DXR shares performed in 2024? Daxor's stock was trading at $9.60 at the beginning of the year. Since then, DXR stock has increased by 3.5% and is now trading at $9.9399. View the best growth stocks for 2024 here. Are investors shorting Daxor? Daxor saw a decline in short interest in March. As of March 31st, there was short interest totaling 7,000 shares, a decline of 13.6% from the March 15th total of 8,100 shares. Based on an average daily volume of 2,700 shares, the short-interest ratio is presently 2.6 days. Currently, 0.4% of the shares of the company are short sold. View Daxor's Short Interest. What other stocks do shareholders of Daxor own? Based on aggregate information from My MarketBeat watchlists, some companies that other Daxor investors own include Merck & Co., Inc. (MRK), Novavax (NVAX), Arbutus Biopharma (ABUS), Abbott Laboratories (ABT), Abiomed (ABMD), Aclaris Therapeutics (ACRS), AngloGold Ashanti (AU), Bellicum Pharmaceuticals (BLCM). How do I buy shares of Daxor? Shares of DXR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:DXR) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersThe #1 Crypto for 2024InvestorPlaceDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Daxor Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
